Sign in
4

Changes in Ownership

Amylyx Pharmaceuticals, Inc. Filed Acc 0001193125-26-017056

Co-Chief Executive Officer sold 138,188 shares at an average $13.59 ($1,877,570)

  • Co-Chief Executive Officer acquired 200,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Klee Justin B. · Co-Chief Executive Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2026-01-15 Exercise or conversion : show line 1 in the form +197,153 $7.57 $1,492,448 3,514,739 D
2026-01-15 Sale : show line 2 in the form −136,193 $13.58 $1,849,869 3,378,546 D
2026-01-16 Exercise or conversion : show line 3 in the form +2,847 $7.57 $21,552 3,381,393 D
2026-01-16 Sale : show line 4 in the form −1,995 $13.89 $27,701 3,379,398 D
Open-market sales · 138,188 sh · avg $13.59 · $1,877,570

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-01-15 Exercise or conversion : show line 5 in the form Stock Option (Right to Buy) −197,153 2,847 D
2026-01-16 Exercise or conversion : show line 6 in the form Stock Option (Right to Buy) −2,847 0 D
Loading xslF345X05/ownership.xml…